Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Ratio (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Equity Ratio for 16 consecutive years, with 0.52 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 23.67% to 0.52 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.52 through Dec 2025, down 23.67% year-over-year, with the annual reading at 0.52 for FY2025, 23.67% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.52 at Myriad Genetics, up from 0.51 in the prior quarter.
  • The five-year high for Equity Ratio was 0.78 in Q2 2022, with the low at 0.51 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.67, with a median of 0.68 recorded in 2023.
  • The sharpest move saw Equity Ratio grew 18.01% in 2021, then decreased 24.33% in 2025.
  • Over 5 years, Equity Ratio stood at 0.73 in 2021, then grew by 0.84% to 0.74 in 2022, then fell by 7.56% to 0.68 in 2023, then fell by 0.12% to 0.68 in 2024, then fell by 23.67% to 0.52 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.52, 0.51, and 0.57 for Q4 2025, Q3 2025, and Q2 2025 respectively.